Advances in Precision Medicine, NGS Testing & Breaking Barriers with Clinical Trials

Life Sciences, Clinical Trials, Healthcare,
  • Friday, May 12, 2023 | 2pm PDT (5pm EDT)
  • 60 min

The National Cancer Institute’s website explains targeted therapies as a type of cancer treatment that targets proteins that control how cancer cells grow, divide, and spread. It is the foundation of precision medicine. As researchers learn more about the DNA changes and proteins that drive cancer, they are better able to design treatments that target these proteins. The purpose of this webinar is to provide an overview of current research of targeted therapies as demonstrated by the efforts of Endeavor Biomedicines and Elevate Oncology.


The webinar will begin with a brief history of previous cancer therapies and lead into current research in up-and-coming targeted therapies, specifically the targeted therapies in development by the sponsor companies. The sponsor companies will provide a short presentation that demonstrates the science behind these therapies, the current clinical trials involving these therapies, data obtained to date and other ongoing trials.

A brief overview of clinical trials will be discussed with topics including, the benefits of choosing a trial as a therapy option, current programs offered to help with barriers associated with clinical trials and how to find the right trial. In addition, a Patient Advocacy Group Representative will present information about resources and their efforts for patients who are trying to navigate their way into new forms of treatment options and how the navigators work from a patient advocacy standpoint.

Read Less...

At the end of the webinar, the featured speakers will open the floor for questions and answers as well as an interactive discussion on clinical trial perception and barriers. Oncology nurses and nurse/patient navigators might especially find this webinar useful, with tools and resources to best help their current and future patients.

Register today to learn more about advances in precision medicine, NGS testing and breaking barriers with clinical trials.



Anita DiFrancesco, VP Clinical Operations, Endeavor BioMedicines

Ms. Anita DiFrancesco has over 25 years of industry experience; primarily with small to mid-size biotech companies. She has designed and managed numerous clinical trials from Phase 1 to Phase 3 in therapeutic areas including oncology, pulmonology, musculoskeletal and pain. Ms. DiFrancesco has built teams and clinical departments from inception to fully functional independent internal teams. Prior to joining Endeavor, Anita was the Vice President of Clinical Operations for Samumed, LLC, where she was responsible for the management and leadership of the Clinical Operations department. Prior to that she worked at Huya Bioscience, Cypress Bioscience and Chiron Corporation. She received her BS from Georgetown University.

Message Presenter

Maegan Deegan, Senior Director, Clinical Operations, Elevation Oncology

Bio coming soon.

Message Presenter

Who Should Attend?

  • Nurse Navigators
  • Patient Advocate Trial Navigators
  • Oncologist
  • Oncology Nurses
  • Oncology Patients
  • Residential Oncologists
  • Patient Advocates

What You Will Learn

Attendees will gain insights into:

  • The definition of targeted therapies and how they differ from traditional therapies
  • Current research in targeted therapies as demonstrated by sponsor compounds
  • Clinical trials in targeted therapies
  • Patient advocacy resources
  • Clinical trial/patient resources
  • Advancements in NGS testing

Xtalks Partners

Endeavor Biomedicines

Endeavor BioMedicines is a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases, including oncology and fibrosis. We combine advancements in technology with an evolving understanding of terminal diseases to develop best-in-class medicines with the potential to reverse the most severe health conditions. We are a highly qualified, innovative and focused team that has come together to live up to our name and bold mission: to help patients feel better and live longer.

Elevation Oncology

Elevation Oncology is a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers. The company was founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. Our most advanced candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account